ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial

Share:

Listens: 0

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Miscellaneous


In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.